GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sprint Bioscience AB (FRA:5JA1) » Definitions » Change In Receivables

Sprint Bioscience AB (FRA:5JA1) Change In Receivables : €-0.37 Mil (TTM As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Sprint Bioscience AB Change In Receivables?

Sprint Bioscience AB's change in receivables for the quarter that ended in Dec. 2024 was €-0.19 Mil. It means Sprint Bioscience AB's Accounts Receivable increased by €0.19 Mil from Sep. 2024 to Dec. 2024 .

Sprint Bioscience AB's change in receivables for the fiscal year that ended in Dec. 2024 was €-0.37 Mil. It means Sprint Bioscience AB's Accounts Receivable increased by €0.37 Mil from Dec. 2023 to Dec. 2024 .

Sprint Bioscience AB's Accounts Receivable for the quarter that ended in Dec. 2024 was €0.04 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Sprint Bioscience AB's Days Sales Outstanding for the three months ended in Dec. 2024 was 2.26.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Sprint Bioscience AB's liquidation value for the three months ended in Dec. 2024 was €-0.65 Mil.


Sprint Bioscience AB Change In Receivables Historical Data

The historical data trend for Sprint Bioscience AB's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sprint Bioscience AB Change In Receivables Chart

Sprint Bioscience AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.37 -0.01 - -0.23 -0.37

Sprint Bioscience AB Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.13 0.05 -0.02 -0.21 -0.19

Sprint Bioscience AB Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.37 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sprint Bioscience AB  (FRA:5JA1) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Sprint Bioscience AB's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0.035/1.414*91
=2.26

2. In Ben Graham's calculation of liquidation value, Sprint Bioscience AB's accounts receivable are only considered to be worth 75% of book value:

Sprint Bioscience AB's liquidation value for the quarter that ended in Dec. 2024 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=2.178-2.85+0.75 * 0.035+0.5 * 0
=-0.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sprint Bioscience AB Change In Receivables Related Terms

Thank you for viewing the detailed overview of Sprint Bioscience AB's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Sprint Bioscience AB Business Description

Traded in Other Exchanges
Address
Halsovagen 7, Floor 8, Elevator A, Novum, Huddinge, SWE, 141 57
Sprint Bioscience AB is a Sweden based company involved in developing drugs focused on cancer and metabolism. The project portfolio of the company includes STK25, VPS34, and PIP4K2.

Sprint Bioscience AB Headlines

No Headlines